A1C and weight outcomes at 18 months in patients with type 2 diabetes treated with exenatide in an ambulatory care setting

被引：2
|
作者：
McAdam-Marx, C. [1 ]
Ye, X. [1 ]
Brixner, D. I. [1 ]
Fabunmi, R. [2 ]
Wintle, M. [2 ]
Boye, K. S. [3 ]
Misurski, D. [3 ]
Nielsen, L. L. [4 ]
机构：
[1] Univ Utah, Pharmacotherapy Outcomes Res Ctr, Salt Lake City, UT 84112 USA
[2] Amylin Pharmaceut Inc, San Diego, CA USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] LLNielsen Med Writing LLC, Ramona, CA USA
来源：
DIABETES OBESITY & METABOLISM | 2009年 / 11卷 / 12期
关键词：
D O I：
10.1111/j.1463-1326.2009.01163.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1173 / 1174
页数：2
相关论文
共 50 条
  • [1] A1C Outcomes at 6 and 18 Months in Insulin Naive Patients with Type 2 Diabetes Treated with Analog Basal Insulin in an Ambulatory Care Setting
    Mcadam-Marx, Carrie
    Brixner, Diana I.
    Xiangyang, Y. E.
    Misurski, Derek
    Fabunmi, Rosalind
    DIABETES, 2009, 58 : A513 - A513
  • [2] Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting
    Brixner, D. I.
    McAdam-Marx, C.
    Ye, X.
    Boye, K. S.
    Nielsen, L. L.
    Wintle, M.
    Misurski, D.
    Fabunmi, R.
    DIABETES OBESITY & METABOLISM, 2009, 11 (12): : 1122 - 1130
  • [3] A1C AND WEIGHT OUTCOMES FOLLOWING 6 MONTHS OF ANALOG BASAL INSULIN IN INSULIN NAIVE PATIENTS WITH TYPE-2 DIABETES IN AN AMBULATORY CARE SETTING
    McAdam-Marx, C.
    Brixner, D.
    Ye, X.
    Misurski, D.
    Fabunmi, R.
    VALUE IN HEALTH, 2009, 12 (03) : A97 - A97
  • [4] 18 MONTH A1C AND WEIGHT OUTCOMES OF EXENATIDE THERAPY IN PATIENTS WITH TYPE-2 DIABETES IN A REAL-WORLD STUDY
    Brixner, D.
    McAdam-Marx, C.
    Ye, X.
    Misurski, D.
    Wintle, M.
    Fabunmi, R.
    VALUE IN HEALTH, 2009, 12 (03) : A97 - A97
  • [5] Antidiabetic Treatment and A1C Testing in Youth with Type 2 Diabetes in an Ambulatory Care Setting
    Mcadam-Marx, Carrie
    Brixner, Diana I.
    Metraux, Stephen
    Moelter, Stephen
    Field, Robert
    DIABETES, 2009, 58 : A514 - A514
  • [6] Estimating the Potential Cardiovascular Benefit of A1c Reduction and Weight Loss in Patients with Type 2 Diabetes Treated with Exenatide for at Least Three Years
    Best, Jennie H.
    Herman, William H.
    Wintle, Matthew
    DIABETES, 2009, 58 : A316 - A316
  • [7] Exenatide (Exendin-4) reduced A1C and weight over 82 weeks in overweight patients with type 2 diabetes
    Blonde, L
    Han, J
    Mac, S
    Poon, T
    Taylor, K
    Kim, D
    DIABETES, 2005, 54 : A118 - A118
  • [8] HEMOGLOBIN A1C (A1C) REDUCTION AND DIABETES-RELATED HEALTH CARE COSTS AMONG TYPE 2 DIABETES (T2DM) PATIENTS TREATED WITH LIRAGLUTIDE OR EXENATIDE: A RETROSPECTIVE CLAIMS DATABASE ANALYSIS
    Mocarski, M.
    Tian, Y.
    Buysman, E. K.
    Wolbeck, R.
    VALUE IN HEALTH, 2016, 19 (07) : A666 - A666
  • [9] Insulin Treated Type 2 Diabetes: Impact of Exenatide on Weight
    Samarasinghe, Yohan P.
    Shlomowitz, Amy
    Munro, Neil
    Feher, Michael D.
    DIABETES, 2009, 58 : A142 - A142
  • [10] Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide
    Paul, S.
    Best, J.
    Klein, K.
    Han, J.
    Maggs, D.
    DIABETES OBESITY & METABOLISM, 2012, 14 (09): : 826 - 834
12345